Newsroom

May 2017

• Press release May 31, 2017

  At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018

  Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020 Focused and taking steps to become…
• Press release May 30, 2017

  Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients

  Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months.CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the…
• Press release May 26, 2017

  Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)

  In ALK-positive metastatic NSCLC patients, Zykadia median progression-free survival (PFS) was 16.6 months, compared to 8.1 months with chemotherapy[1]  The overall intracranial response rate…
• 
  Story May 25, 2017 Discovery

  Going global to meet local needs in China

  Marc Pelletier traveled from Cambridge, MA to Shanghai, China, to launch new lines of research for the treatment of cancers that are common in China.

• 
  Story May 25, 2017 Patient Perspectives

  Choosing the right care

  Melanoma survivor T.J. Sharpe shares why patients should know their treatment options.

• Press release May 23, 2017

  Novartis' new analyses reinforce the potential of Ultibro® Breezhaler® for COPD patients historically treated with steroids

  New analyses from the FLAME study suggest dual bronchodilator Ultibro® Breezhaler® provides similar or better efficacy versus steroid-containing therapies, regardless of blood eosinophil (a type of…
• Press release May 19, 2017

  Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)

  Phase III trial, first-line treatment with Zykadia resulted in improved progression-free survival (PFS) over SOC chemotherapy with maintenance, including in patients with brain metastases[1]…
• Press release May 18, 2017

  Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care

  Updated analyses from the Kisqali® pivotal Phase III MONALEESA-2 trial in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer to be…
• Press release May 17, 2017

  Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities

  Better Hearts Better Cities is a Novartis Foundation initiative to improve cardiovascular health in low-income urban communities by addressing the prevention, management and control of hypertension…
• 
  Story May 15, 2017 Discovery

  Women in Science: Renee Rodgers

• 
  Story May 15, 2017 Access to Healthcare

  Novartis invites scrutiny of effort to improve access to medicine

  Public health expert Richard Laing discusses how independent measurement of access programs can help ensure their success

• In The News May 12, 2017

  Novartis Access and government of Pakistan sign memorandum of understanding

  Novartis reaches agreement with Pakistan to increase access to medicines that address the rapid rise of chronic illness among poor people in the world's sixth most populous nation.